[1] Then S , Raymond A .An update on HLA alleles as pharmacogenetic markers for antiepileptic drug-induced cutaneous adverse reaction［J］．Neuroscience Research Notes, 2019.DOI:10.31117/NEUROSCIRN.V2I2.29.[2] Micheletti RG, Chiesa-Fuxench Z, Noe MH, et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol 2018: 138: 2315-21.[3] Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994:331: 1272-85.[4] Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014: 312: 525-34.[5] Kesavan R, Narayan SK, Adithan C. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients. Eur J Clin Pharmacol 2010: 66: 689-96.[6] Kerr H, Wong E, Makou E, et al. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem 2017: 292: 13345-60.[7] McCormack M, Gui H, Ingason A, et al. Genetic variation in CFH predicts phenytoin induced maculopapular exanthema in European-descent patients. Neurology 2018: 90: e332-e41.[8] 廖卫平．抗癫痫药物所致不良反应的研究进展［J］．癫痫杂志，2019(004):005.[9] Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010: 11: 349-56.[10] Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine induced cutaneous adverse reactions in Asians. Neurology 2017: 88: 78-86.[11] Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011: 20: 1034-41.[12] Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013:54: 1307-14.[13] Zhou B T , Zhou Q H , Yin J Y ,et al.Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.［J］．Cns Neuroscience&Therapeutics,2012,18(7):566-572.DOI:10.1111/j.1755-5949.2012.00321.x.[14] Niihara H , Kakamu T , Fujita Y ,et al.HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population.［J］．JournalofDermatology,2012,39(7):594-601.DOI:10.1111/j.1346-8138.2011.01457.x.[15] Whirl-Carrillo M, Huddart R, Gong L, et al. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine［J］． Clin Pharmacol Ther. 2021;110(3):563-572. DOI:10.1002/cpt.2350[16] Ramírez E, Bellón T, Tong HY, et al. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population［J］． Pharmacol Res. 2017;115:168-178. DOI:10.1016/j.phrs.2016.11.027[17] Nakkam N, Konyoung P, Amornpinyo W, et al. Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine［J］． Br J Clin Pharmacol. 2022;88(2):773-786. DOI:10.1111/bcp.15022[18] Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy［J］．Epilepsy Research, 2015, 117:52-57.DOI:10.1016/j.eplepsyres.2015.09.001.